Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study

Andre, T.Amonkar, M.Norquist, J.Shiu, K-K.Kim, T. W.Jensen, B. V.Jensen, L. H.Punt, C. J.Smith, D.Garcia-Carbonero, R.Sevilla, I.de la Fouchardiere, C.Rivera, F.Elez, E.Diaz, L. A.Yoshino, T.Van Cutsem, E.Yang, P.Farooqui, M. Z. H.Le, D.2025-01-072025-01-072020-09-010923-7534https://hdl.handle.net/10668/26993enHealth-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 studyconference outputopen access10.1016/j.annonc.2020.08.5071569-8041http://www.annalsofoncology.org/article/S0923753420405034/pdf573469100396